Cooley Advises Underwriters on Immune Design IPO

New York – August 11, 2014 – Cooley LLP announced today that it advised the underwriters on Immune Design Corp.'s $63 million IPO. Immune Design is a clinical-stage immunotherapy company with next-generation approaches designed to enable the body's immune system to fight disease. The company trades on The NASDAQ Global Market under the symbol "IMDZ."

Jefferies LLC and Leerink Partners LLC acted as the joint book-running managers and Wells Fargo Securities, LLC acted as the lead manager for the offering.

The Cooley corporate securities team advising the underwriters included partners Div Gupta, David Peinsipp and Charlie Kim, and associates Carolyn Mo, Kristin VanderPas and Pia Kaur. Critical support for the offering was provided by partners Natasha Leskovsek and Wendy Goldstein, special counsel Phil Mitchell and associate Jennifer Shanley (health care and life sciences regulatory); partner Bill Christiansen (intellectual property); partner Renee Deming and associate Justin Ho (compensation and benefits); and partner Susan Philpot (tax).

Thus far in 2014, Cooley has advised on 73 public offerings, including 37 completed IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
Susan Cooper Philpot Partner, San Francisco
David Peinsipp Partner, San Francisco
Natasha Leskovsek Partner, Washington, DC
Renee Deming Retired Partner, Palo Alto
Bill Christiansen Partner, Seattle
Kristin VanderPas Partner, San Francisco
Wendy Goldstein Partner, New York
Phil Mitchell Partner, New York
Pia Kaur Associate, New York
Div Gupta Partner, New York